Page 1

Exhibit 99.3 ADC THERAPEUTICS ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates ZYNLONTA ™ ( loncastuximab tesirine - lpyl ) granted accelerated FDA approval for patients with relapsed or refractory diffuse large B- cell lymphoma - Commercial launch progressing well ; orders shipped NCCN guidelines category 2A recommendation to reflect the broad FDA indication Company to host conference call today at 8:30 a.m. EDT Lausanne , Switzerland , May 6 , 2021 - ADC Therapeutics SA ( NYSE : ADCT ) , a commercial - stage biotechnology company leading the development of novel antibody drug conjugates ( ADCs ) to treat hematological malignancies and solid tumors , today reported financial results for the first quarter ended March 31 , 2021 and provided business updates . " We are off to an exciting start to the year with the recent accelerated FDA approval of ZYNLONTA ™ , bringing a new and differentiated treatment option to patients with relapsed or refractory diffuse large B - cell lymphoma , " said Chris Martin , Chief Executive Officer of ADC Therapeutics . " ZYNLONTA is approved for a broad population of r / r DLBCL patients , including DLBCL NOS , DLBCL arising from low grade lymphoma and also high - grade B - cell lymphoma . This reflects the real world population of patients enrolled in our LOTIS - 2 pivotal trial including transplant eligible and ineligible patients , heavily pre - treated patients and patients with difficult - to - treat disease . In addition , we continue to advance our pipeline of next - generation ADCs for patients with difficult - to - treat hematologic and solid tumor cancers . " " On the occasion of the commercial launch of ZYNLONTA , it has been impressive to see the high quality of talented and experienced commercial and medical affairs professionals at ADC Therapeutics fully prepared for an early FDA approval , " said Ron Squarer , Chairman of the Board and an advisor to the Company . " This team is executing on its launch plan and is well equipped to support the treating community in adopting an important new option with a broad label which included tough to treat patients in third - line plus DLBCL . " Recent Highlights ZYNLONTA ( loncastuximab tesirine - lpyl ) • • FDA accelerated approval and launch : ZYNLONTA was granted accelerated approval by the U.S. Food and Drug Administration ( FDA ) on April 23 , 2021 , as a single - agent for the treatment of adult patients with relapsed or refractory large B - cell lymphoma after two or more lines of systemic therapy , including diffuse large B - cell lymphoma ( DLBCL ) not otherwise specified , DLBCL arising from low grade lymphoma , and high - grade B - cell lymphoma , a key point of differentiation on the label . ZYNLONTA became commercially available last week and the commercial launch is fully underway . Added to the National Comprehensive Cancer Network ( NCCN ) Clinical Practice Guidelines in Oncology : As of May 5 , 2021 , ZYNLONTA was added to the NCCN guidelines with a category 2A recommendation for third - line plus DLBCL , including DLBCL arising from low - grade lymphoma such as follicular lymphoma ( FL ) and marginal zone lymphoma ( MZL ) .